Explore the promising potential of Altimmune, Inc.'s Pemvidutide in NASH, AUD, & obesity treatment, with key trials underway.

The result suggests that the protein made by the gene, known as Nwd1, and other molecules it interacts with could be ...

HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the launch of their first Laboratory Developed Test (LDT) FibroSIGHT™ – now ...

Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated ...

THR-beta agonists are the only medication approved to treat metabolic dysfunction–associated steatohepatitis (MASH), a severe ...

MASH has long been a challenging and progressive liver disease, characterized by fat build-up and inflammation that, if left untreated, leads to fibr ...

Medically reviewed by Jay N. Yepuri, MD Metabolic dysfunction-associated steatohepatitis (MASH) is an advanced form of ...

Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025Commercial launch in the PRC of generic nintedanib for the ...

Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated ...

Metabolic dysfunction-associated steatohepatitis (MASH) is a polygenic disorder influenced by multiple genes, but their ...

MASH is marked by lipid droplet accumulation in the liver, progressing from steatosis to inflammation and cell damage, ultimately leading to fibrosis, cirrhosis, and hepatocellular carcinoma.